Sheffield Angels Make First Investment in Ethical Biotech Pioneer - Sansanima

May 2025 – Sheffield, UK – Sheffield Angels is proud to announce its inaugural investment in Sansanima, a University of Sheffield spinout revolutionising pharmaceutical safety testing. This milestone investment marks the beginning of Sheffield Angels’ mission to support high-impact, science-led innovation across the region and beyond.

Sansanima has developed a pioneering human cell-based testing platform that offers a compelling ethical and technical alternative to traditional animal testing in the production of life-saving medicines, including vaccines for tetanus and botulinum toxin-based therapies. The company’s breakthrough aligns with recent moves by global regulators, including the US FDA, to phase out mandatory animal testing – signalling a growing global demand for modern, humane solutions.

Seven Sheffield Angel investors participated in the round, joined by o2h Ventures, a member of the Cambridge Angels network. This collaboration reinforces the strong and growing ties between the Sheffield and Cambridge Angel communities, sharing a common vision for backing cutting-edge science and ethical innovation.

With patents secured across the US, EU, South Korea, and Japan, and early validation from the UK’s MHRA, Sansanima is already engaging with international vaccine manufacturers to bring its platform to market.

Dr. Andy Evans, Co-Chair of Sheffield Angels, commented:

“We are thrilled to support Sansanima in their mission to modernise pharmaceutical safety testing. This investment reflects our commitment to backing outstanding local science with global relevance, and marks a fantastic start for Sheffield Angels, setting the tone for a future focused on responsible innovation, regional growth, and national impact.”

Ciara Doren, CEO of Sansanima, said:

“We’re delighted to have Sheffield Angels and o2h Ventures join us on our journey. Their support not only validates the scientific and ethical impact of our platform but also strengthens our ability to bring humane, cutting-edge testing solutions to global pharmaceutical partners. It’s especially meaningful to have the backing of investors who understand both the regional innovation landscape and the broader international opportunity.”

About Sheffield Angels:

Sheffield Angels is a network of experienced investors and entrepreneurs dedicated to supporting early-stage science and technology ventures emerging from the Sheffield region. Inspired by the model of Cambridge Angels, the group fosters high-quality deal flow, member engagement, and strategic collaboration across the UK innovation ecosystem.

About Sansanima:

Sansanima is a University of Sheffield spinout developing next-generation safety testing platforms that reduce reliance on animal models. Its human cell-based assays deliver more accurate, efficient, and ethical results, with global applicability in regulatory and commercial pharmaceutical testing.